Projects
| Project Code | Principal Investigator (PI), Co-PI, if any | Funding Agency | Title of the Project | Objectives | Amount Received (INR (in Lacs.)) |
|---|---|---|---|---|---|
| GP-252 | Dr. U. C. Banerjee | - | - | - | 419.82 |
| GP-398 | Dr. M. E. Sobhia | DST | The challenges of new drug discovery for oral anti diabetic drugs: Molecular dynamics simulations, pharmacophore modeling and molecular design of PTP1B allosteric inhibitors. | Details | 25.00 |
| GP-399 | Dr. M. E. Sobhia | CSIR | Studies on PTPIB allosteric inhibitors: In silico design, biological applications and protein crystallization. | Details | 14.82 |
| GP-400 | Dr. Arvind K Bansal | DST | Development and evaluation of Nanocrystalline Solid Dispersion of a poorly water soluble drug. | Details | 17.00 |
| GP-401 | Dr. J. K. Laha | SERB | Development of metal - catalyzed domino synthesis of azafluorenes and its applications in the synthesis of compounds potential as aromatase inhibitors, natural product, and in the discovery of new amine protecting group. | Details | 46.50 |
| GP-404 | Dr. A. H. Pande | DST | Generation and characterization of improved variant(s) of SsoPox enzyme as organophoaphate - degrading agent. | Details | 25.00 |
| GP-405 | Dr. Sankar K. Guchhait | CSIR | Natural product inspired novel heterocyclic antitubulin anticancer agents: Design, synthesis and bio - evaluation studies. | Details | 10.50 |
| GP-406 | Dr. Arvind K Bansal Dr. A.T. Sangamwar (Co-PI) | DBT | Nanocrystalline solid dispersion of polyphenols (curcumin and hesperetin) with enhanced oral bioavailability for cancer treatment. | Details | 11.88 |
| GP-407 | Dr. Ipsita Roy | SERB | Exploring the role of aging on chaperone - mediated protein folding in a yeast model of Huntington's disease. | Details | 26.25 |
| GP-408 | Dr. P. V. Bharatam | DST | Multiscale modelling of pharmaceutically relevant drug dendrimer nano scale complexes. | Details | 40.00 |
| GP-409 | Dr. Inder Pal Singh | DIHAR-DRDO | Biologically active secondary metabolites from Codonopsis clematidea of trans Himalayas. | Details | 6.50 |
| GP-410 | Dr. Ipsita Roy | DBT | Regulated expression of RNA aptamers for inhibition of protein aggregation. | Details | 36.98 |
| GP-411 | Dr. Inder Pal Singh, Sanjai Saxena (Thapar University, Patiala) Dr. Manmohan Chhibber (Co-PI) | DBT | Isolation and characterization of xanthine oxidase inhibitors from endophytic fungi for treatment of hyperurecemia and gout. | Details | 13.70 |
| GP-412 | Dr. Dipika Bansal Dr. Prabha Garg (Co-PI) | ICMR | Comparative efficacy, safety and Generalized cost-effectiveness of commonly used medications in Chronic Low Back Pain: A Bayesian multiple treatment comparison analysis. | Details | 4.21 |
| GP-413 | Dr. K B Tikoo | SERB | Elucidation of role of DNA methylation in emergence of insulin resistance. | Details | 23.95 |
| GP-414 | Dr. G. B. Jena | DST | Influence of Nrf2-ARE signaling pathways on the genetic and epigenetic modifications in the germ cells of diabetic rat: Role of zinc and selenium. | Details | 10.53 |
| GP-415 | Dr. Arvind K Bansal | BIRAC | Enhancement of oral bioavailability of poorly water soluble drugs using NanoCrySP* technology, *A patented nanocrystalline solid dispersion technology platform developed at NIPER, S.A.S. Nagar. | Details | 31.10 |
| GP-416 | Dr. Sankar K. Guchhait | SERB | Switch in mode of action of Ellipticine with Etoposide-inspired structural modulation: Towards exploration of new molecular motifs as potential anticancer agents. | Details | 27.35 |
| GP-417 | Dr. A. T. Sangamwar | DBT | Computational and in vitro screening of bioflavonoids for selective P-gp inhibition. | Details | 15.40 |
| GP-418 | Dr. Chaaya Iyengar | DBT (NWBA) | Mutagenesis of M.tuberculosis Glyceraldehyde-3-phosphate dehydrogenase (M.tb GAPDH) to identify key residues involved in protein multifunctionality. | Details | 5.00 |
| GP-419 | Dr. Chaaya Iyengar Dr. Ipsita Roy (Co-PI) | DBT | Regulation and Mechanism of M.tb Glyceraldehyde-3-phosphate dehydrogenase in transferrin iron uptake. | Details | 24.77 |
| GP-420 | Prof. I. P. Singh, Dr. Dharamvir Arya (AIIMS, New Delhi) Dr. Kulbhushan Tikoo, Prof. Arvind Bansal, Dr. Dinesh Kumar (IHBT) (Co-PI) Prof. Kamlesh Bhutani, Prof. Sanjay Jachak, Dr. Mahesh Gupta (IHBT), Dr. G. B. Jena, Dr. Ashok Singh (IHBT), Dr. Ruma Ray (AIIMS), Dr. Tapas Nag (AIIMS), Dr. Jagriti Bhatia (AIIMS) | DBT | Development of herbal formulations from Seabuckthorn. | Details | 98.89 |
| GP-421 | Dr. Sanyog Jain | DST | Lipid conjugate based & nontech driven approaches for oral /systemic delivery of amphotericin B in efficient management of visceral leishmaniasis & systemic fungal infection. | Details | 37.07 |
| GP-422 | Dr. Arvind K Bansal | ICMR | Pre-clinical Development of Penicillin Drug Delivery System for Prophylaxis of Rheumatic Heart Disease. | Details | 32.24 |
| GP-423 | Dr. Chaaya Iyengar | DST | Lactoferrin mediated iron uptake via Mycobacterium tuberculosis Glyceraldehyde-3-phophate dehydrogenase. | Details | 7.62 |
| GP-424 | Dr. Sanyog Jain | BIRAC SRISTI GYTI |
Design and development of novel protein stabilized multiple emulsion with permeation enhancer to improve oral bioavailability of insulin. | Details | 3.75 |
| CNF-160 | Dr. Sanyog Jain Dr. Rajan Swamy (Post Doc) |
SERB | Advanced non viral nano-nucleotherapeutics to enhance gene silencing through localised cytoplasmic delivery. | Details | 9.60 |
| CNF-161 | Dr. Sanyog Jain Dr. K B Tikoo (Mentor) |
SERB | Development of RNA aptamer conjugated nanoparticle-5hmdC and 5fdC targeting cytidine deaminase expressing cancer cells. | Details | 18.70 |
| CNF-162 | Dr. Saima Malik | SERB | Synthesis of Marine Alkaloid Mansouramycin D and Structure Activity Relationship (SAR) study. | Details | 9.60 |
| Title of the Project | Funding Agency | Principal Investigator (PI) / Co-PIs | Duration | Amount Received (INR (in Lacs.)) |
|---|---|---|---|---|
| Stereoselective synthesis of chiral alcohols of pharmaceutical importance via microbial oxidoreductases: Process development and scale-up (Multi-Institutional) | DBT | Dr. U. C. Banerjee (Multi-Institutional) | 2013-2016 | 80.0 |
| Studies on anti-tumor and radioprotective potential of Potentila fulgens Wall ex Hook and characterization of its active compounds | DBT | Dr. U. C. Banerjee | 2011-2014 | 83.0 |
| Enantioselective enzymatic synthesis of (S)-1-bromo-3-chloro- 2-propanol, an intermediate for the chiral drugs | CSIR | Dr. U. C. Banerjee | 2010-2013 | 20.0 |
| Enhancement of oral bioavailability of melatonin and evaluation of radio-protective efficacy in mice | INMAS-DRDO | Dr. Arvind K Bansal | Completed in December 2014 | |
| Design and characterization of nano-crystalline solid dispersions< | D B T | Dr. Arvind K Bansal | C ompleted in 2010 | |
| Salt forms for optimization of biopharmaceutical properties of drug substances | DST | Dr. Arvind K Bansal | Completed in 2009 | |
| Development of optimized formulations of curcumin | D B T | Dr. Arvind K Bansal | Completed in 2009 | |
| Identification of potential anti-HIV natural product analogs using molecular docking and medicinal chemistry approaches | D B T , ICMR | Dr. Inder Pal Singh | May, 2013-April, 2017 | 80.30 |
| Isolation of anthocyanins from berries | University of Louisville | Dr. Inder Pal Singh | January, 2007 -June, 2015 | 35,000 (USD) |
| Comparative chemoprofiling, isolation and characterization of secondary metabolites of Rhodiola imbricata and Rhodiola heterodanta | DIHAR-DRDO | Dr. Inder Pal Singh | October, 2011-September, 2014 | 9.50 |
| Natural product inspired novel heterocyclic antitubulin anticancer agents: Design, synthesis and bio-evaluation studies | CSIR | Dr. Sankar K. Guchhait | October, 2014 (3 years) | 19.50 |
| The relevance of host and Mycobacterial GAPDH during infection . | DST | Dr. Chaaya Iyengar | July 2013-2016 | 38 .10 |
| Role of Mycobacterial GAPDH in Iron uptake . | D B T | Dr. Chaaya Iyengar | November 2010-2014 | 52 . 49 |
| Role of GAPDH as a multifunctional protein in Dendritic cells . | DST Women ' s Scientist Scheme (A) project | Dr. Chaaya Iyengar | August 2006- August 2009 | 16 . 08 |
| Development of smart nanoconstructs as non-viral vectors for site specific gene delivery | Indian National Science Academy (INSA) | Dr. Sanyog Jain | November, 2012 - October, 2015 | 15.00 |
| Development of smart nanocarriers for oral vaccine delivery | DBT under Nanotechnology Programme | Dr. Sanyog Jain | April, 2010 - June, 2015 | 28.81 |
| Development and Characterization of functionalized carbon nanotubes for tumor drug targeting and therapy | ICMR under Nanomedicine Program | Dr. Sanyog Jain | November, 2010 - October, 2013 | 49.88 |
| Design of polyelectrolyte coated multilayered liposomes (stable liposomes) for oral insulin delivery | DST-SYSP programme | Dr. Sanyog Jain | April, 2010 - March, 2013 | 21.52 |
| Centre for Pharmaceutical Nanotechnology | DST | Dr. Sanyog Jain/ Dr. Arvind K. Bansal | July, 2008 - June, 2012 | 959.5 |
| Role of sirtuins in modulating cell metabolism in Leishmania donovani and its potential as chemotherapeutic target. | CSIR | Dr. Sushma Singh | February, 2014 (03 years) | 20.00 |
| Characterization of eukaryotic initiation factor 5a of Leishmania donovani and its efficacy as drug target. | DST | Dr. Sushma Singh | 2015 (03 years) | 11.00 |
| A program project proposal for target specific drug discovery research against Kala Azar. | Department of Pharmaceuticals (DoP) (Govt. of India) | Multi-PI project | April 2017, 03 years | 92.00 |